Salmeterol Dosage
This dosage information may not include all the information needed to use Salmeterol safely and effectively. See additional information for Salmeterol.
The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.
Usual Adult Dose for:
Usual Pediatric Dose for:
Additional dosage information:
Usual Adult Dose for Asthma - Maintenance
Inhalation powder: 1 puff (50 mcg) every 12 hours.
Usual Adult Dose for Chronic Obstructive Pulmonary Disease - Maintenance
Inhalation powder: 1 puff (50 mcg) every 12 hours.
Usual Adult Dose for Bronchospasm Prophylaxis
Prevention of Exercise Induced Asthma:
Inhalation powder: 1 puff (50 mcg) 30 to 60 minutes before exercise.
Usual Pediatric Dose for Asthma - Maintenance
Children at least 4 years of age:
Inhalation powder: 1 puff (50 mcg) every 12 hours.
Usual Pediatric Dose for Chronic Obstructive Pulmonary Disease - Maintenance
Children at least 4 years of age:
Inhalation powder: 1 puff (50 mcg) every 12 hours.
Usual Pediatric Dose for Bronchospasm Prophylaxis
Prevention of Exercise Induced Asthma:
Children at least 4 years of age:
Inhalation powder: 1 puff (50 mcg) 30 to 60 minutes before exercise.
Renal Dose Adjustments
Data not available
Liver Dose Adjustments
Data not available
Precautions
Salmeterol is not intended for the treatment of acute bronchospasm.
Patients who are using salmeterol twice daily should not take additional doses prior to exercise. Consider other therapy if twice daily salmeterol is not effective during exercise.
For long-term asthma control, long-acting beta-2 agonists should be used in combination with inhaled corticosteroids and not as monotherapy.
Because long-acting beta-2 agonists (LABAs) may disguise poorly controlled persistent asthma, frequent or chronic use of LABAs for exercise induced bronchospasm is discouraged by the NIH Asthma Guidelines (NIH, 2007).
Dialysis
Data not available
Other Comments
The US FDA requires a Risk Evaluation and Mitigation Strategy (REMS) for salmeterol. It includes a Medication Guide and communication plan. Additional information is available at www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm111350.htm.
